Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs Oxybutynin for Neurogenic Detrusor Overactivity in SCI
NCT03187795Phase 2Unknown
- Sponsor
- Kessler Foundation
- Start
- Apr 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirabegron in neurogenic detrusor overactivity (NDO), sponsored by Kessler Foundation. Status: unknown.
02
Drugs
mirabegron
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT03187795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187795.